Physician profile
Andrew Gregory
NPI 1396312500
$1,074.23
in general payments reported to CMS, 2019-2025
15 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2023: $41.90 · 2024: $320 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.37 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $93.65 | 2024-2025 | Gvoke Hypopen |
| Dexcom, INC. | $93.40 | 2024-2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $80.46 | 2024 | Prolastin-C Liquid |
| Exact Sciences Corporation | $72.49 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $65.83 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $62.59 | 2024-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $58.26 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $45.40 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $34.34 | 2025 | Ozempic |
| Astellas Pharma US INC | $33.80 | 2025 | Veozah |
| Lilly USA, LLC | $30.84 | 2024-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $24.99 | 2025 | Voquezna |
| Shield Therapeutics INC | $19.02 | 2025 | |
| Corcept Therapeutics | $18.48 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.